DNER and hematologic disorder: In this in vivo study, since JQ1 is not being considered in clinical trials because of its short half-life, we utilized the clinically relevant BET inhibitor OTX015, which is in multiple clinical trials in patients with solid tumors or hematologic malignancies [25].